Description: Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Home Page: www.adynxx.com
100 Pine Street
San Francisco,
CA
94111
United States
Phone:
415-512-7740
Officers
| Name | Title |
|---|---|
| Mr. Richard Orr Esq., J.D. | Pres, CEO, Principal Financial Officer & Director |
| Dr. Julien Mamet Ph.D. | Founder, Chief Scientific Officer & Director |
| Mr. William Martin | Exec. VP of Corp. Devel. & Operations |
| Ms. Dina Gonzalez | Principal Accounting Officer & Sr. VP of Fin. |
| Ms. Kimberley Hebert | Sr. Director of Clinical Operations |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.0926 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |